Alkeon Capital Management
CERE

Alkeon Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Alkeon Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-699,695
Closed -$22.2M – 118
2023
Q2 		$22.2M Sell
699,695
-36,826
-5% -$1.13M 0.04% 95
2023
Q1 		$18M Sell
736,521
-327,880
-31% -$9.62M 0.04% 102
2022
Q4 		$33.6M Sell
1,064,401
-104,195
-9% -$2.94M 0.13% 94
2022
Q3 		$33M Sell
1,168,596
-42,383
-3% -$1.26M 0.11% 108
2022
Q2 		$32M Sell
1,210,979
-486,397
-29% -$13.8M 0.09% 108
2022
Q1 		$59.4M Sell
1,697,376
-211,659
-11% -$6.18M 0.12% 110
2021
Q4 		$61.9M Sell
1,909,035
-1,217,400
-39% -$43M 0.11% 101
2021
Q3 		$92.2M Buy
3,126,435
+480,000
+18% +$13.5M 0.16% 103
2021
Q2 		$67.8M Buy
2,646,435
+896,435
+51% +$12.8M 0.1% 111
2021
Q1 		$24M Hold
1,750,000
– – 0.04% 135
2020
Q4 		$29M Buy
+1,750,000
New +$22.7M 0.05% 130

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Alkeon Capital Management's CERE Position: Q3 2023 in Review

Alkeon Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 699,695 shares — an estimated $22.2M sold.

Alkeon Capital Management first reported a position in CERE in Q4 2020 and held it in 11 quarters. The position peaked at $92.2M in Q3 2021. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Alkeon Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Alkeon Capital Management sold 699,695 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $22.2M.
  • Alkeon Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
  • Alkeon Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $92.2M in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Alkeon Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.